Invectys is a biopharmaceutical company that specializes in the development of innovative immunotherapy approaches to treat cancers. Founded in 2010 by two veterans from the Institut Pasteur, Invectys has made remarkable advancements in the field of oncology. Their team of scientists has pioneered two groundbreaking platforms of oncology products, which have now reached the clinical stage.

One of their key focuses is the HLA-G immune checkpoint, a highly prevalent tumor antigen found in over 50% of cancers. Invectys has created advanced HLA-G technological platforms to exploit the potential of this specific antigen. By mobilizing and restoring the anti-tumor capacity of the immune system in cancer patients, Invectys aims to target virtually all types of cancers.

The company has received significant recognition for its scientific advances and has raised over $60 million in funding. With a strong emphasis on innovation, Invectys offers a promising and cost-effective alternative to traditional oncology approaches. They are actively pursuing partnerships with pharmaceutical companies and have a talented and seasoned team driving their success